CA2382387C - Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure - Google Patents
Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure Download PDFInfo
- Publication number
- CA2382387C CA2382387C CA002382387A CA2382387A CA2382387C CA 2382387 C CA2382387 C CA 2382387C CA 002382387 A CA002382387 A CA 002382387A CA 2382387 A CA2382387 A CA 2382387A CA 2382387 C CA2382387 C CA 2382387C
- Authority
- CA
- Canada
- Prior art keywords
- stroke
- prevention
- chf
- pharmaceutically acceptable
- heart failure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Abstract
The present invention relates to use of an inhibitor of the renin-angiotensi n system (RAS) or a pharmaceutically acceptable derivative thereof, particular ly ramipril or ramiprilat, in the manufacture of a medicament for the preventio n of stroke, diabetes and/or congestive heart failure (CHF). The present invention further relates to a method of prevention and/or treatment of stroke, diabetes and/or CHF, comprising administering a therapeutically effective amount of an inhibitor of the RAS or a pharmaceutically acceptable derivative thereof, particularly ramipril or ramiprilat, to a patient in nee d of such prevention and/or treatment.
Description
Pharmaceutical Formulations And Use Thereof In The Prevention Of Stroke, Diabetes And/Or Congestive Heart Failure FIELD OF INVENTION
The present invention relates to use of an inhibitor of the renin-angiotensin system (RAS) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the prevention of stroke, diabetes and /or congestive heart failure (CHF). The present invention further relates to a method of prevention and/or treatment of stroke, diabetes and/or CHF; comprising administering a therapeutically effective amount of an inhibitor of the RAS or a pharmaceutically acceptable derivative thereof to a patient in need of such prevention and/or treatment.
BACKGROUND OF THE INVENTION
Compounds that interfere with the RAS are well known in the art and are used to treat cardiovascular diseases, particularly arterial hypertension and heart failure.
Principally, the RAS can be interferred with by inhibition of the enzymes synthesizing angiotensins or by blocking the corresponding receptors at the effector sites.
Available today are inhibitors of the angiotensin converting enzyme (ACE) and angiotensin II type 1 receptor (AT II) antagonists.
ACE inhibitors are compounds which inhibit the conversion of angiotensin I
into the active angiotensin II as well as the breakdown of the active vasodilator bradykinin.
Both of these mechanisms lead to vasodilation. Such compounds have been described in, for example, EP 158927, EP 317878, US 4,743,450, and US
4, 857, 520.
Ramipril (disclosed in EP-A-079022) is a long-acting ACE inhibitor. Its active metabolite is the free diacid ramiprilat, which is obtained in vivo upon administration of ramipril. In hypertensive patients administration of ramipril is known to cause a reduction in peripheral arterial resistance and thus a reduction of the blood pressure without a compensatory rise in heart rate. It is currently being used in the treatment of hypertension and CHF. Furthermore, ramipril has been shown to reduce mortality CONFIRMATION COPY
WO 01/15673 CA 02382387 2002-02-26 pCT/EP00/08341 in patients with clinical signs of congestive heart failure after surviving an acute myocardial infarction. Ramipril has been suggested to have an added advantage over many other ACE inhibitors due to its pronounced inhibition of ACE in tissues resulting in organ protective effects in e.g. the heart, kidney, and blood vessels.
Compounds that interfere with the RAS including ACE inhibitors and AT II
antagonists are currently used in the treatment of various cardiovascular disorders, especially in patients exhibiting a high blood pressure. Use of said compounds in prevention of cardiovascular disorders is much less common and the use of said compounds in the prevention of stroke, diabetes and /or CHF is hitherto unknown.
SUMMARY OF THE INVENTION
The present invention relates to use of an inhibitor of the RAS or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the prevention of stroke, especially in patients exhibiting normal or low blood pressure.
The present invention further relates to use of an inhibitor of the RAS or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the prevention of diabetes.
The present invention also relates to use of an inhibitor of the RAS or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the prevention of development of CHF in patients with no preexisting CHF, i.e. no signs or symptoms of CHF.
Another aspect of the invention is a method of prevention of stroke, diabetes and/or CHF, comprising administering a therapeutically effective amount of an inhibitor of the RAS or a pharmaceutically acceptable derivative thereof, to a patient in need of such prevention.
The present invention relates to use of an inhibitor of the renin-angiotensin system (RAS) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the prevention of stroke, diabetes and /or congestive heart failure (CHF). The present invention further relates to a method of prevention and/or treatment of stroke, diabetes and/or CHF; comprising administering a therapeutically effective amount of an inhibitor of the RAS or a pharmaceutically acceptable derivative thereof to a patient in need of such prevention and/or treatment.
BACKGROUND OF THE INVENTION
Compounds that interfere with the RAS are well known in the art and are used to treat cardiovascular diseases, particularly arterial hypertension and heart failure.
Principally, the RAS can be interferred with by inhibition of the enzymes synthesizing angiotensins or by blocking the corresponding receptors at the effector sites.
Available today are inhibitors of the angiotensin converting enzyme (ACE) and angiotensin II type 1 receptor (AT II) antagonists.
ACE inhibitors are compounds which inhibit the conversion of angiotensin I
into the active angiotensin II as well as the breakdown of the active vasodilator bradykinin.
Both of these mechanisms lead to vasodilation. Such compounds have been described in, for example, EP 158927, EP 317878, US 4,743,450, and US
4, 857, 520.
Ramipril (disclosed in EP-A-079022) is a long-acting ACE inhibitor. Its active metabolite is the free diacid ramiprilat, which is obtained in vivo upon administration of ramipril. In hypertensive patients administration of ramipril is known to cause a reduction in peripheral arterial resistance and thus a reduction of the blood pressure without a compensatory rise in heart rate. It is currently being used in the treatment of hypertension and CHF. Furthermore, ramipril has been shown to reduce mortality CONFIRMATION COPY
WO 01/15673 CA 02382387 2002-02-26 pCT/EP00/08341 in patients with clinical signs of congestive heart failure after surviving an acute myocardial infarction. Ramipril has been suggested to have an added advantage over many other ACE inhibitors due to its pronounced inhibition of ACE in tissues resulting in organ protective effects in e.g. the heart, kidney, and blood vessels.
Compounds that interfere with the RAS including ACE inhibitors and AT II
antagonists are currently used in the treatment of various cardiovascular disorders, especially in patients exhibiting a high blood pressure. Use of said compounds in prevention of cardiovascular disorders is much less common and the use of said compounds in the prevention of stroke, diabetes and /or CHF is hitherto unknown.
SUMMARY OF THE INVENTION
The present invention relates to use of an inhibitor of the RAS or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the prevention of stroke, especially in patients exhibiting normal or low blood pressure.
The present invention further relates to use of an inhibitor of the RAS or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the prevention of diabetes.
The present invention also relates to use of an inhibitor of the RAS or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the prevention of development of CHF in patients with no preexisting CHF, i.e. no signs or symptoms of CHF.
Another aspect of the invention is a method of prevention of stroke, diabetes and/or CHF, comprising administering a therapeutically effective amount of an inhibitor of the RAS or a pharmaceutically acceptable derivative thereof, to a patient in need of such prevention.
Yet another aspect of the invention is a pharmaceutical formulation for use in the prevention of stroke, diabetes and/or CHF, comprising a therapeutically effective amount of an inhibitor of the RAS or a pharmaceutically acceptable derivative thereof.
A further aspect of the invention is the use of an inhibitor of the RAS or a pharmaceutically acceptable derivative thereof, in the prevention of stroke, diabetes and/or CHF, by administering the inhibitor of the RAS or a pharmaceutically acceptable derivative thereof, to a patient in need of such prevention.
DETAILED DESCRIPTION OF THE INVENTION
It has surprisingly been found that cardiovascular and metabolic disorders such as stroke, diabetes and CHF can be prevented by use of an inhibitor of RAS, particularly an ACE inhibitor that interferes with the synthesis of angiotensin II. The present invention is especially surprising in that especially patients with an essentially maintained heart function and/or exhibiting a normal or low blood pressure benefit markedly from the preventive action of the inhibitors of RAS. The invention describes a new method to prevent disorders such as stroke, diabetes and/or CHF by administration of an inhibitor of the RAS.
Patients exhibiting a normal or low blood pressure are known as normotensive patients. Examples of guidelines defining blood pressure values for different patient groups including different ages, include guidelines issued by the WHO and JNC(USA). In the present invention, a suitable definition of a normal or low blood pressure can be found in JNC VI.
In the present invention, "stroke" includes both fatal and non-fatal.
In the present invention, "diabetes" include both type I diabetes, also known as insulin-dependent, diabetes mellitus (IDMM), and type II diabetes, also known as non-insulin-dependent diabetes mellitus (NIDDM).
A further aspect of the invention is the use of an inhibitor of the RAS or a pharmaceutically acceptable derivative thereof, in the prevention of stroke, diabetes and/or CHF, by administering the inhibitor of the RAS or a pharmaceutically acceptable derivative thereof, to a patient in need of such prevention.
DETAILED DESCRIPTION OF THE INVENTION
It has surprisingly been found that cardiovascular and metabolic disorders such as stroke, diabetes and CHF can be prevented by use of an inhibitor of RAS, particularly an ACE inhibitor that interferes with the synthesis of angiotensin II. The present invention is especially surprising in that especially patients with an essentially maintained heart function and/or exhibiting a normal or low blood pressure benefit markedly from the preventive action of the inhibitors of RAS. The invention describes a new method to prevent disorders such as stroke, diabetes and/or CHF by administration of an inhibitor of the RAS.
Patients exhibiting a normal or low blood pressure are known as normotensive patients. Examples of guidelines defining blood pressure values for different patient groups including different ages, include guidelines issued by the WHO and JNC(USA). In the present invention, a suitable definition of a normal or low blood pressure can be found in JNC VI.
In the present invention, "stroke" includes both fatal and non-fatal.
In the present invention, "diabetes" include both type I diabetes, also known as insulin-dependent, diabetes mellitus (IDMM), and type II diabetes, also known as non-insulin-dependent diabetes mellitus (NIDDM).
In the present invention, "inhibitor of the renin-angiotensin system (RAS) or a pharmaceutically acceptable derivative thereof' includes any compound which in itself or upon administration blocks the negative effects of angiotensin II on the vasculature either by reducing the synthesis of angiotensin II or blocking its effect at the receptor.
In the present invention, "angiotensin converting enzyme (ACE) inhibitor or a pharmaceutically acceptable derivative thereof' includes any compound which in itself or upon administration interferes with the synthesis of angiotensin II.
When the inhibitor of the RAS used in the present invention have several asymetric carbon atoms, they can consequently exist in several stereochemical forms. The present invention includes the mixture of isomers as well as the individual stereoisomers. The present invention further includes geometrical isomers, rotational isomers, enantiomers, racemates and diastereomers.
Where applicable, the inhibitors of RAS may be used in neutral form, e.g. as a carboxylic acid, or in the form of a salt, preferably a pharmaceutically acceptable salt such as the sodium, potassium, ammonium, calcium or magnesium salt of the compound at issue. Where applicable the compounds listed above can be used in hydrolyzable ester form.
In the present invention, the inhibitors of the RAS include all prodrugs thereof, whether active or inactive in vitro. Thus, although such protected derivatives may not possess pharmacological activity per se, they may be administered e.g.
parenterally or orally, and thereafter metabolized in vivo to form pharmacologically active inhibitors of RAS. Preferred examples are ramipril, which is metabolized into ramiprilat, and candesartan cilexetil, which is metabolized into candesartan.
Inhibitors of the RAS include ACE inhibitors, AT II antagonists, also known as angiotensin receptor blockers (ARBs), renin antagonists, and vasopeptidase inhibitors (VPIs).
In the present invention, "angiotensin converting enzyme (ACE) inhibitor or a pharmaceutically acceptable derivative thereof' includes any compound which in itself or upon administration interferes with the synthesis of angiotensin II.
When the inhibitor of the RAS used in the present invention have several asymetric carbon atoms, they can consequently exist in several stereochemical forms. The present invention includes the mixture of isomers as well as the individual stereoisomers. The present invention further includes geometrical isomers, rotational isomers, enantiomers, racemates and diastereomers.
Where applicable, the inhibitors of RAS may be used in neutral form, e.g. as a carboxylic acid, or in the form of a salt, preferably a pharmaceutically acceptable salt such as the sodium, potassium, ammonium, calcium or magnesium salt of the compound at issue. Where applicable the compounds listed above can be used in hydrolyzable ester form.
In the present invention, the inhibitors of the RAS include all prodrugs thereof, whether active or inactive in vitro. Thus, although such protected derivatives may not possess pharmacological activity per se, they may be administered e.g.
parenterally or orally, and thereafter metabolized in vivo to form pharmacologically active inhibitors of RAS. Preferred examples are ramipril, which is metabolized into ramiprilat, and candesartan cilexetil, which is metabolized into candesartan.
Inhibitors of the RAS include ACE inhibitors, AT II antagonists, also known as angiotensin receptor blockers (ARBs), renin antagonists, and vasopeptidase inhibitors (VPIs).
5 The phrase "vasopeptidase inhibitors" embraces so-called NEP/ACE inhibitors (also referred to as selective or dual acting neutral endopeptidase inhibitors) which possess neutral endopeptidase (NEP) inhibitory activity and angiotensin converting enzyme (ACE) inhibitory activity.
The phrase "renin antagonists" embraces renin inhibitors.
In the present invention, the RAS inhibitors may exhibit a long term duration, medium term duration or short term duration.
ACE inhibitors or pharmaceutically acceptable derivatives thereof, including active metabolites, which can be used for the prevention of stroke, diabetes and/or CHF
include, but is not limited to, the following compounds:
alacepril, alatriopril, altiopril calcium, ancovenin, benazepril, benazepril hydrochloride, benazeprilat, benzoylcaptopril, captopril, captopril-cysteine, captopril-glutathione, ceranapril, ceranopril, ceronapril, cilazapril, cilazaprilat, delapril, delapril-diacid, enalapril, enalaprilat, enapril, epicaptopril, foroxymithine, fosfenopril, fosenopril, fosenopril sodium, fosinopril, fosinopril sodium, fosinoprilat, fosinoprilic acid, glycopril, hemorphin-4, idrapril, imidapril, indolapril, indolaprilat, libenzapril, lisinopril, lyciumin A, lyciumin B, mixanpril, moexipril, moexiprilat, moveltipril, muracein A, muracein B, muracein C, pentopril, perindopril, perindoprilat, pivalopril, pivopril, quinapril, quinapril hydrochloride, quinaprilat, ramipril, ramiprilat, spirapril, spirapril hydrochloride, spiraprilat, spiropril, spiropril hydrochloride, temocapril, temocapril hydrochloride, teprotide, trandolapril, trandolaprilat, utibapril, zabicipril, zabiciprilat, zofenopril and zofenoprilat.
Preferred ACE inhibitors for use in the present invention are camipril, ramiprilat, lisinopril, enalapril and enalaprilat. More preferred ACE inhibitors for uses in the WO 01/15673 CA 02382387 2002-02-26 pCT/EP00/08341 present invention are ramipril and ramiprilat. Information about ramipril and ramiprilat can be obtained e.g. from the Merck Index., 12t" ed., 1996, pp. 1394-1395.
AT II antagonists or pharmaceutically acceptable derivatives thereof, including active metabolites, which can be used for the prevention of stroke, diabetes and/or CHF
include, but is not limited to, those described in European Patent Applications, Publication Nos. 253310, 323841, 324377, 399731, 400974, 401030, 403158, 403159, 407102, 407342, 409332, 411507, 411766, 412594, 412848, 415886, 419048, 420237, 424317, 425211, 425921, 426021, 427463, 429257, 430300, 430709, 432737, 434038, 434249, 435827, 437103, 438869, 442473, 443568, 443983, 445811, 446062, 449699, 450566, 453210, 454511, 454831, 456442, 456442, 456510, 459136, 461039, 461040, 465323, 465368, 467207, 467715, 468372, 468470, 470543, 475206, 475898, 479479, 480204, 480659, 481448, 481614, 483683, 485929, 487252, 487745, 488532, 490587, 490820, 492105, 497121, 497150, 497516, 498721, 498722, 498723, 499414, 499415, 499416, 500297, 500409, 501269, 501892, 502314, 502575, 502725, 503162, 503785, 503838, 504888, 505098, 505111, 505893, 505954, 507594, 508393, 508445, 508723, 510812, 510813, 511767, 511791, 512675, 512676, 512870, 513533, 513979, 514192, 514193, 514197, 514198, 514216, 514217, 515265, 515357, 515535, 515546, 515548, 516392, 517357, 517812, 518033, 518931, 520423, 520723, 520724, 521768, 522038, 523141, 526001, 527534, and 528762. Other AI I
antagonists include those disclosed in International Patent Application, Publication Nos. WO 91 /00277, WO 91 /00281, WO 91 /11909, WO 91 /11999, WO 91 /12001, WO 91 /12002, WO 91 /13063, 91 /15209, WO 91 /15479, WO 91 /16313, WO
91/17148, WO 91/18888, WO 91/19697, WO 91/19715, WO 92/00067, WO
92/00068, WO 92/00977, WO 92/02510, WO 92/04335, WO 92/04343, WO
92/05161, WO 92/06081, WO 92/07834, WO 92/07852, WO 92/09278, WO
92/09600, WO 92/10189, WO 92/11255, WO 92/14714, WO 92/16523, WO
92/16552, WO 92/17469, WO 92/18092, WO 92/19211, WO 92/20651, WO
92/20660, WO 92/20687, WO 92/21666, WO 92/22533, WO 93/00341, WO
93/01177, WO 93/03018, WO 93/03033 and WO 93/03040. The contents of the aforesaid European and International Patent Applications.
Preferred AT II antagonists or pharmaceutically acceptable derivatives thereof for use in the present invention include, but is not limited to, compounds with the following generic names: candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, tasosartan, telmisartan and eprosartan.
Particularly preferred AT II antagonists or pharmaceutically acceptable derivatives thereof for use in the present invention are candesartan and candesartan cilexetil. Candesartan and candesartan cilexetil are known from European Patent No. 459 13681, US 5,196,444 and US 5,703,110 to Takeda Chemical Industries. Candesartan cilexetil is currently manufactured and sold world-wide by AstraZeneca and Takeda. e. g. under the trade names Atacand~, Amias~ and Blopress~.
NEP/ACE-inhibitors or pharmaceutically acceptable derivatives thereof, including active metabolites, which can be used for the prevention of stroke, diabetes and/or CHF include, but is not limited to, those compounds disclosed in U.S. Patents Nos. 5,508,272, 5,362,727, 5,366,973, 5,225,401, 4,722,810, 5,223,516, 5,552,397, 4,749,688, 5,504,080, 5,612,359, 5,525,723, 5,430,145, and 5,679,671, and European Patent Applications 0481522, 0534263, 0534396, 0534492 and 0671172.
Preferred NEP/ACE inhibitors for use in the present invention are those which are designated as preferred in the above U.S. patents and European Patent Applications. Especially preferred is the NEP/ACE inhibitor omapatrilat (disclosed in U.S. Patent No. 5,508,272), or MDL100240 (disclosed in U.S.
Patent No. 5,430,145).
Renin-inhibitors or pharmaceutically acceptable derivatives thereof, including active metabolites, which can be used for the prevention of stroke, diabetes and/or CHF include, but is not limited to, the following compounds:
The phrase "renin antagonists" embraces renin inhibitors.
In the present invention, the RAS inhibitors may exhibit a long term duration, medium term duration or short term duration.
ACE inhibitors or pharmaceutically acceptable derivatives thereof, including active metabolites, which can be used for the prevention of stroke, diabetes and/or CHF
include, but is not limited to, the following compounds:
alacepril, alatriopril, altiopril calcium, ancovenin, benazepril, benazepril hydrochloride, benazeprilat, benzoylcaptopril, captopril, captopril-cysteine, captopril-glutathione, ceranapril, ceranopril, ceronapril, cilazapril, cilazaprilat, delapril, delapril-diacid, enalapril, enalaprilat, enapril, epicaptopril, foroxymithine, fosfenopril, fosenopril, fosenopril sodium, fosinopril, fosinopril sodium, fosinoprilat, fosinoprilic acid, glycopril, hemorphin-4, idrapril, imidapril, indolapril, indolaprilat, libenzapril, lisinopril, lyciumin A, lyciumin B, mixanpril, moexipril, moexiprilat, moveltipril, muracein A, muracein B, muracein C, pentopril, perindopril, perindoprilat, pivalopril, pivopril, quinapril, quinapril hydrochloride, quinaprilat, ramipril, ramiprilat, spirapril, spirapril hydrochloride, spiraprilat, spiropril, spiropril hydrochloride, temocapril, temocapril hydrochloride, teprotide, trandolapril, trandolaprilat, utibapril, zabicipril, zabiciprilat, zofenopril and zofenoprilat.
Preferred ACE inhibitors for use in the present invention are camipril, ramiprilat, lisinopril, enalapril and enalaprilat. More preferred ACE inhibitors for uses in the WO 01/15673 CA 02382387 2002-02-26 pCT/EP00/08341 present invention are ramipril and ramiprilat. Information about ramipril and ramiprilat can be obtained e.g. from the Merck Index., 12t" ed., 1996, pp. 1394-1395.
AT II antagonists or pharmaceutically acceptable derivatives thereof, including active metabolites, which can be used for the prevention of stroke, diabetes and/or CHF
include, but is not limited to, those described in European Patent Applications, Publication Nos. 253310, 323841, 324377, 399731, 400974, 401030, 403158, 403159, 407102, 407342, 409332, 411507, 411766, 412594, 412848, 415886, 419048, 420237, 424317, 425211, 425921, 426021, 427463, 429257, 430300, 430709, 432737, 434038, 434249, 435827, 437103, 438869, 442473, 443568, 443983, 445811, 446062, 449699, 450566, 453210, 454511, 454831, 456442, 456442, 456510, 459136, 461039, 461040, 465323, 465368, 467207, 467715, 468372, 468470, 470543, 475206, 475898, 479479, 480204, 480659, 481448, 481614, 483683, 485929, 487252, 487745, 488532, 490587, 490820, 492105, 497121, 497150, 497516, 498721, 498722, 498723, 499414, 499415, 499416, 500297, 500409, 501269, 501892, 502314, 502575, 502725, 503162, 503785, 503838, 504888, 505098, 505111, 505893, 505954, 507594, 508393, 508445, 508723, 510812, 510813, 511767, 511791, 512675, 512676, 512870, 513533, 513979, 514192, 514193, 514197, 514198, 514216, 514217, 515265, 515357, 515535, 515546, 515548, 516392, 517357, 517812, 518033, 518931, 520423, 520723, 520724, 521768, 522038, 523141, 526001, 527534, and 528762. Other AI I
antagonists include those disclosed in International Patent Application, Publication Nos. WO 91 /00277, WO 91 /00281, WO 91 /11909, WO 91 /11999, WO 91 /12001, WO 91 /12002, WO 91 /13063, 91 /15209, WO 91 /15479, WO 91 /16313, WO
91/17148, WO 91/18888, WO 91/19697, WO 91/19715, WO 92/00067, WO
92/00068, WO 92/00977, WO 92/02510, WO 92/04335, WO 92/04343, WO
92/05161, WO 92/06081, WO 92/07834, WO 92/07852, WO 92/09278, WO
92/09600, WO 92/10189, WO 92/11255, WO 92/14714, WO 92/16523, WO
92/16552, WO 92/17469, WO 92/18092, WO 92/19211, WO 92/20651, WO
92/20660, WO 92/20687, WO 92/21666, WO 92/22533, WO 93/00341, WO
93/01177, WO 93/03018, WO 93/03033 and WO 93/03040. The contents of the aforesaid European and International Patent Applications.
Preferred AT II antagonists or pharmaceutically acceptable derivatives thereof for use in the present invention include, but is not limited to, compounds with the following generic names: candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, tasosartan, telmisartan and eprosartan.
Particularly preferred AT II antagonists or pharmaceutically acceptable derivatives thereof for use in the present invention are candesartan and candesartan cilexetil. Candesartan and candesartan cilexetil are known from European Patent No. 459 13681, US 5,196,444 and US 5,703,110 to Takeda Chemical Industries. Candesartan cilexetil is currently manufactured and sold world-wide by AstraZeneca and Takeda. e. g. under the trade names Atacand~, Amias~ and Blopress~.
NEP/ACE-inhibitors or pharmaceutically acceptable derivatives thereof, including active metabolites, which can be used for the prevention of stroke, diabetes and/or CHF include, but is not limited to, those compounds disclosed in U.S. Patents Nos. 5,508,272, 5,362,727, 5,366,973, 5,225,401, 4,722,810, 5,223,516, 5,552,397, 4,749,688, 5,504,080, 5,612,359, 5,525,723, 5,430,145, and 5,679,671, and European Patent Applications 0481522, 0534263, 0534396, 0534492 and 0671172.
Preferred NEP/ACE inhibitors for use in the present invention are those which are designated as preferred in the above U.S. patents and European Patent Applications. Especially preferred is the NEP/ACE inhibitor omapatrilat (disclosed in U.S. Patent No. 5,508,272), or MDL100240 (disclosed in U.S.
Patent No. 5,430,145).
Renin-inhibitors or pharmaceutically acceptable derivatives thereof, including active metabolites, which can be used for the prevention of stroke, diabetes and/or CHF include, but is not limited to, the following compounds:
enalkrein; RO 42-5892; A 65317; CP 80794; ES 1005; ES 8891; SQ 34017; CGP
29287; CGP 38560; SR 43845; U-71038; A 62198; and A 64662.
Pharmaceutical formulations In one aspect, the present invention relates to pharmaceutical formulations comprising as active ingredient an RAS inhibitor or a pharmaceutically acceptable derivative or prod rug thereof, including metabolites, for use in the prevention of stroke, diabetes and/or conge-stive heart failure (CHF).
For clinical use, the RAS inhibitor is formulated into a pharmaceutical formulation for oral, intravenous, subcutaneous, tracheal, bronchial, intranasal, pulmonary, transdermal, buccal, rectal, parenteral or some other mode of administration.
The pharmaceutical formulation may contain the inhibitor in admixture with a pharmaceutically acceptable adjuvant, diluent and/or carrier.
In the preparation of the pharmaceutical formulations of the present invention the active ingredient may be mixed with solid, powdered ingredients, such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes. The mixture may then be processed into granules or pressed into tablets.
The active ingredient may be separately premixed with the other, non-active ingredients, before being mixed to form a formulation.
Soft gelatine capsules may be prepared with capsules containing a mixture of the active ingredient of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatine capsules. Hard gelatine capsules may contain granules of the active ingredients. Hard gelatine capsules may also contain the active ingredients in combination with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatine.
Dosage units for rectal administration may be prepared (i) in the form of suppositories which contain the active substance mixed with a neutral fat base; (ii) in the form of a gelatine rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil or other suitable vehicle for gelatine rectal capsules;
(iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.
Liquid preparations may be prepared in the form of syrups or suspensions, e.g.
solutions or suspensions containing the active ingredients and the remainder consisting, for example, of sugar or sugar alcohols and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid preparations may contain coloring agents, flavoring agents, preservatives, saccharine and carboxymethyl cellulose or other thickening agents. Liquid preparations may also be prepared in the form of a dry powder to be recon-stituted with a suitable solvent prior to use.
Solutions for parenteral administration may be prepared as a solution of a formulation of the invention in a pharmaceutically acceptable solvent. These solutions may also contain stabilizing ingredients, preservatives and/or buffering ingredients. Solutions for parenteral administration may also be prepared as a dry preparation to by reconstituted with a suitable solvent before use.
The total amount of active ingredient suitably lies in the range of from about 0.1 (w/w) to about 95 % (w/w) of the formulation, suitably from 0.5 % to 50 %
(w/w) and preferably from 1 % to 25 % (w/w).
The pharmaceutical formulations may contain between about 0.1 mg and about mg of active ingredient, preferably between 1 mg and 100 mg of active ingredient.
The dose of the active ingredient to be administered will depend on the relevant indication, the age, weight and sex of the patient and may be determined by a physician. The dosage will suitably be in the range of from about 0.01 mg/kg to about 5 20 mg/kg, preferably between 0.1 mg/kg and 10 mg/kg.
The typical daily dose of the active ingredients varies within a wide range and will depend on various factors such as the relevant indication, the route of administration, the age, weight and sex of the patient and may be determined by a 10 physician. In general, dosages, and especially oral and parenteral dosages, will be in the range of from about 0.1 to about 100 mg per day of active ingredient, preferably between 1 and 50 mg per day of active ingredient.
The following Example is intended to illustrate, but in no way limit the scope of the invention.
EXAMPLE
A large-scale clinical trial was designed to examine the effect of the ACE
inhibitor ramipril versus placebo in reducing cardiovascular events.
The study was conducted in 267 centres in 19 countries over a six year period and included 9,541 participants who are at high risk for cardiovascular events due to a history of previous ischaemic heart disease, stroke, peripheral arterial disease or individuals with diabetes.
The systolic blood pressure at inclusion of the patients was on average 138 mm Hg and thus the patients were normotensive at study start. After one month of therapy with either ramipril or placebo, the systolic blood pressure had decreased by 5.48 mm Hg and 1.59 mm Hg, respectively.
The primary endpoint of the study was myocardial infarction (MI), stroke and cardiovascular (CV) death (mortality).
W~ 01/15673 CA 02382387 2002-02-26 pCT/EP00/08341 The study was stopped early because of a very clear reduction in the combined endpoint of cardiovascular deaths, heart attacks and strokes in patients taking ramipril. In addition to the above benefits, there was also a reduction of between a fourth and a fifth in the need for revascularisation procedures (such as coronary artery bypass graft surgery, balloon angioplasty, etc.) and diabetic complications.
There was a clear 32% reduction in the ramipril group in the number of patients who developed a stroke, and this is surprising since patients were normotensive when recruited to the study.
The number of patients who developed CHF was significantly reduced by 21% in the ramipril group, which is unexpected since patients had no signs or symptoms of CHF
at study start.
Equally surprising is the marked 36% reduction in the number of patients who developed diabetes in the ramipril group.
Abbrevations ACE = angiotensin converting enzyme AT II = angiotensin II type 1 receptor CHF = congestive heart failure IDMM = insulin-dependent, diabetes mellitus JNC = Joint National Committee MI = myocardial infarction NIDDM = non-insulin-dependent diabetes mellitus WHO = World Health Organization
29287; CGP 38560; SR 43845; U-71038; A 62198; and A 64662.
Pharmaceutical formulations In one aspect, the present invention relates to pharmaceutical formulations comprising as active ingredient an RAS inhibitor or a pharmaceutically acceptable derivative or prod rug thereof, including metabolites, for use in the prevention of stroke, diabetes and/or conge-stive heart failure (CHF).
For clinical use, the RAS inhibitor is formulated into a pharmaceutical formulation for oral, intravenous, subcutaneous, tracheal, bronchial, intranasal, pulmonary, transdermal, buccal, rectal, parenteral or some other mode of administration.
The pharmaceutical formulation may contain the inhibitor in admixture with a pharmaceutically acceptable adjuvant, diluent and/or carrier.
In the preparation of the pharmaceutical formulations of the present invention the active ingredient may be mixed with solid, powdered ingredients, such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes. The mixture may then be processed into granules or pressed into tablets.
The active ingredient may be separately premixed with the other, non-active ingredients, before being mixed to form a formulation.
Soft gelatine capsules may be prepared with capsules containing a mixture of the active ingredient of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatine capsules. Hard gelatine capsules may contain granules of the active ingredients. Hard gelatine capsules may also contain the active ingredients in combination with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatine.
Dosage units for rectal administration may be prepared (i) in the form of suppositories which contain the active substance mixed with a neutral fat base; (ii) in the form of a gelatine rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil or other suitable vehicle for gelatine rectal capsules;
(iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.
Liquid preparations may be prepared in the form of syrups or suspensions, e.g.
solutions or suspensions containing the active ingredients and the remainder consisting, for example, of sugar or sugar alcohols and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid preparations may contain coloring agents, flavoring agents, preservatives, saccharine and carboxymethyl cellulose or other thickening agents. Liquid preparations may also be prepared in the form of a dry powder to be recon-stituted with a suitable solvent prior to use.
Solutions for parenteral administration may be prepared as a solution of a formulation of the invention in a pharmaceutically acceptable solvent. These solutions may also contain stabilizing ingredients, preservatives and/or buffering ingredients. Solutions for parenteral administration may also be prepared as a dry preparation to by reconstituted with a suitable solvent before use.
The total amount of active ingredient suitably lies in the range of from about 0.1 (w/w) to about 95 % (w/w) of the formulation, suitably from 0.5 % to 50 %
(w/w) and preferably from 1 % to 25 % (w/w).
The pharmaceutical formulations may contain between about 0.1 mg and about mg of active ingredient, preferably between 1 mg and 100 mg of active ingredient.
The dose of the active ingredient to be administered will depend on the relevant indication, the age, weight and sex of the patient and may be determined by a physician. The dosage will suitably be in the range of from about 0.01 mg/kg to about 5 20 mg/kg, preferably between 0.1 mg/kg and 10 mg/kg.
The typical daily dose of the active ingredients varies within a wide range and will depend on various factors such as the relevant indication, the route of administration, the age, weight and sex of the patient and may be determined by a 10 physician. In general, dosages, and especially oral and parenteral dosages, will be in the range of from about 0.1 to about 100 mg per day of active ingredient, preferably between 1 and 50 mg per day of active ingredient.
The following Example is intended to illustrate, but in no way limit the scope of the invention.
EXAMPLE
A large-scale clinical trial was designed to examine the effect of the ACE
inhibitor ramipril versus placebo in reducing cardiovascular events.
The study was conducted in 267 centres in 19 countries over a six year period and included 9,541 participants who are at high risk for cardiovascular events due to a history of previous ischaemic heart disease, stroke, peripheral arterial disease or individuals with diabetes.
The systolic blood pressure at inclusion of the patients was on average 138 mm Hg and thus the patients were normotensive at study start. After one month of therapy with either ramipril or placebo, the systolic blood pressure had decreased by 5.48 mm Hg and 1.59 mm Hg, respectively.
The primary endpoint of the study was myocardial infarction (MI), stroke and cardiovascular (CV) death (mortality).
W~ 01/15673 CA 02382387 2002-02-26 pCT/EP00/08341 The study was stopped early because of a very clear reduction in the combined endpoint of cardiovascular deaths, heart attacks and strokes in patients taking ramipril. In addition to the above benefits, there was also a reduction of between a fourth and a fifth in the need for revascularisation procedures (such as coronary artery bypass graft surgery, balloon angioplasty, etc.) and diabetic complications.
There was a clear 32% reduction in the ramipril group in the number of patients who developed a stroke, and this is surprising since patients were normotensive when recruited to the study.
The number of patients who developed CHF was significantly reduced by 21% in the ramipril group, which is unexpected since patients had no signs or symptoms of CHF
at study start.
Equally surprising is the marked 36% reduction in the number of patients who developed diabetes in the ramipril group.
Abbrevations ACE = angiotensin converting enzyme AT II = angiotensin II type 1 receptor CHF = congestive heart failure IDMM = insulin-dependent, diabetes mellitus JNC = Joint National Committee MI = myocardial infarction NIDDM = non-insulin-dependent diabetes mellitus WHO = World Health Organization
Claims (8)
OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A use of ramipril or ramiprilat or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention or reduction of the risk of cardiovascular death in a normotensive patient at high risk for a cardiovascular event due to a history of previous ischemic heart disease, stroke or peripheral arterial disease and with no signs or symptoms of congestive heart failure (CHF).
2. A use of ramipril or ramiprilat or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention or reduction of the risk of congestive heart failure (CHF) in a normotensive patient at high risk for a cardiovascular event due to a history of previous ischemic heart disease, stroke or peripheral arterial disease and with no signs or symptoms of congestive heart failure (CHF).
3. A use of ramipril or ramiprilat or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention or reduction of the risk of a myocardial infarction in a normotensive patient at high risk for a cardiovascular event due to a history of previous ischemic heart disease, stroke or peripheral arterial disease and with no signs or symptoms of congestive heart failure (CHF).
4. The use according to any one of claims 1 - 3, where the patient is diabetic.
5. A use of ramipril or ramiprilat or a pharmaceutically acceptable salt thereof for the prevention or reduction of the risk of cardiovascular death in a normotensive patient at high risk for a cardiovascular event due to a history of previous ischemic heart disease, stroke or peripheral arterial disease and with no signs or symptoms of congestive heart failure (CHF).
6. A use of ramipril or ramiprilat or a pharmaceutically acceptable salt thereof for the prevention or reduction of the risk of congestive heart failure (CHF) in a normotensive patient at high risk for a cardiovascular event due to a history of previous ischemic heart disease, stroke or peripheral arterial disease and with no signs or symptoms of congestive heart failure (CHF).
7. A use of ramipril or ramiprilat or a pharmaceutically acceptable salt thereof for the prevention or reduction of the risk of a myocardial infarction in a normotensive patient at high risk for a cardiovascular event due to a history of previous ischemic heart disease, stroke or peripheral arterial disease and with no signs or symptoms of congestive heart failure (CHF).
8. The use according to any one of claims 5 - 7, where the patient is diabetic.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002500709A CA2500709A1 (en) | 2000-08-25 | 2000-08-25 | Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9903028A SE9903028D0 (en) | 1999-08-27 | 1999-08-27 | New use |
SE9903028-0 | 1999-08-27 | ||
PCT/EP2000/008341 WO2001015673A2 (en) | 1999-08-27 | 2000-08-25 | Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002500709A Division CA2500709A1 (en) | 2000-08-25 | 2000-08-25 | Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2382387A1 CA2382387A1 (en) | 2001-03-08 |
CA2382387C true CA2382387C (en) | 2005-06-21 |
Family
ID=20416770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002382387A Expired - Fee Related CA2382387C (en) | 1999-08-27 | 2000-08-25 | Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
Country Status (36)
Country | Link |
---|---|
US (6) | US20060194868A1 (en) |
EP (4) | EP2277519A3 (en) |
JP (1) | JP4843172B2 (en) |
KR (2) | KR20020060167A (en) |
CN (2) | CN101537181A (en) |
AT (2) | ATE554761T1 (en) |
AU (3) | AU7648400A (en) |
BG (2) | BG66115B1 (en) |
BR (1) | BR0013540A (en) |
CA (1) | CA2382387C (en) |
CY (2) | CY1112987T1 (en) |
CZ (1) | CZ303433B6 (en) |
DE (1) | DE60023518T3 (en) |
DK (3) | DK1437131T3 (en) |
EE (1) | EE05130B1 (en) |
ES (3) | ES2525699T3 (en) |
HK (1) | HK1050327A1 (en) |
HR (1) | HRP20020169A2 (en) |
HU (1) | HU229107B1 (en) |
IL (1) | IL148126A (en) |
ME (1) | ME00181B (en) |
MX (1) | MXPA02001633A (en) |
NO (2) | NO329245B1 (en) |
NZ (1) | NZ571901A (en) |
PL (1) | PL353066A1 (en) |
PT (2) | PT1925303E (en) |
RS (1) | RS52907B (en) |
RU (2) | RU2272651C2 (en) |
SE (1) | SE9903028D0 (en) |
SI (3) | SI1437131T1 (en) |
SK (1) | SK288239B6 (en) |
TR (5) | TR200202464T2 (en) |
UA (2) | UA76702C2 (en) |
WO (1) | WO2001015673A2 (en) |
YU (1) | YU3602A (en) |
ZA (1) | ZA200201471B (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020040795A (en) | 1999-08-30 | 2002-05-30 | 로버트 흐라이탁, 미쉘 베스트 | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
KR20030083010A (en) * | 2001-03-26 | 2003-10-23 | 고토부키 세이야쿠 가부시키가이샤 | Isoquinuclidine derivative, process for producing the same, and medicinal composition containing the same |
WO2003032965A2 (en) * | 2001-10-17 | 2003-04-24 | King Pharmaceuticals Research And Development, Inc | Use of ace inhibitors for reducing type 2 diabetes in high risk patients |
US6844361B2 (en) | 2002-02-04 | 2005-01-18 | Aventis Pharma Deutschland Gmbh | Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor |
DE10230272A1 (en) * | 2002-07-05 | 2004-01-22 | Solvay Pharmaceuticals Gmbh | 1 receptor antagonist for the prevention of secondary stroke |
EP1382334A1 (en) * | 2002-07-11 | 2004-01-21 | Université de Picardie Jules Verne | Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke |
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
DE10306179A1 (en) * | 2003-02-13 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Composition useful for preventing stroke comprises dipyridamole or its salt, acetyl salicylic acid and an angiotensin II antagonist |
US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
WO2004080482A2 (en) * | 2003-03-11 | 2004-09-23 | Institut De Cardiologie De Montréal / | Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure |
WO2004096228A1 (en) | 2003-04-25 | 2004-11-11 | Novacardia, Inc. | Method of improved diuresis in individuals with impaired renal function |
EP1687006B1 (en) * | 2003-11-18 | 2007-11-14 | Solvay Pharmaceuticals GmbH | Pharmaceutical compositions for the treatment of renal dysfunction |
BRPI0508880A (en) * | 2004-03-17 | 2007-09-04 | Novartis Ag | use of organic compounds |
ZA200704767B (en) * | 2004-11-05 | 2008-08-27 | King Pharmaceuticals Res & Dev | Stabilized individually coated ramipril particles, compositions and methods |
WO2007044910A1 (en) * | 2005-10-13 | 2007-04-19 | Duke University | Compositions for the treatment and prevention of heart disease and methods of using same |
CA2661598A1 (en) * | 2006-08-28 | 2008-03-06 | Sanofi-Aventis Deutschland Gmbh | Methods of lowering glucose levels |
DK2180787T3 (en) | 2007-08-01 | 2014-02-03 | Univ Pittsburgh | NITROOLIC ACID MODULATION OF TYPE II DIABETES |
ES2692291T3 (en) | 2008-05-01 | 2018-12-03 | Complexa Inc. | Vinyl substituted fatty acids |
WO2009155439A2 (en) | 2008-06-19 | 2009-12-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
CA2733790A1 (en) | 2008-08-20 | 2010-02-25 | Ensemble Discovery Corporation | Macrocyclic compounds for inhibition of tumor necrosis factor alpha |
JP2013500966A (en) | 2009-07-31 | 2013-01-10 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | Fatty acids as anti-inflammatory agents |
EP2483233A4 (en) | 2009-10-02 | 2013-08-14 | Complexa Inc | Heteroatom containing substituted fatty acids |
EP2568893B1 (en) | 2010-05-14 | 2015-06-24 | Sabanci Universitesi | An apparatus for using hydrodynamic cavitation in medical treatment |
WO2013028501A1 (en) | 2011-08-19 | 2013-02-28 | The University Of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
WO2016176338A1 (en) * | 2015-04-30 | 2016-11-03 | The Trustees Of Columbia University In The City Of New York | Small molecule ras ligands |
PL3865484T3 (en) | 2015-07-07 | 2024-04-22 | H. Lundbeck A/S | Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases |
KR20180098222A (en) | 2015-10-02 | 2018-09-03 | 컴플렉사, 인코포레이티드 | Prevention, treatment and reversal of diseases using therapeutically effective amounts of activated fatty acids |
KR20210014662A (en) | 2018-05-25 | 2021-02-09 | 이마라 인크. | 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1, 5-a]Pyrazin-8-one monohydrate and crystalline form |
CN110833620A (en) * | 2018-08-15 | 2020-02-25 | 王镕 | Use of angiotensin converting enzyme inhibitors for the prevention and treatment of autoimmune diseases and the corresponding complications |
KR20230137654A (en) * | 2022-03-22 | 2023-10-05 | 주식회사 메디포럼 | A composition for preventing and treating stroke |
Family Cites Families (256)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5612114B2 (en) * | 1974-06-07 | 1981-03-18 | ||
US4231938A (en) * | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DK149080C (en) * | 1980-06-06 | 1986-07-28 | Sankyo Co | METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES |
US4450171A (en) * | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
ZA817261B (en) * | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
DE3226768A1 (en) * | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | DERIVATIVES OF CIS, ENDO-2-AZABICYCLO- (3.3.0) -OCTAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THE MEANS CONTAINING THEM AND THE USE THEREOF |
US4448784A (en) * | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
US4722810A (en) | 1984-08-16 | 1988-02-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
DE3413710A1 (en) | 1984-04-12 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | METHOD FOR TREATING HEART INSUFFICIENCY |
US5684016A (en) * | 1984-04-12 | 1997-11-04 | Hoechst Aktiengesellschaft | Method of treating cardiac insufficiency |
US5231080A (en) * | 1985-10-15 | 1993-07-27 | Hoechst Aktiengesellschaft | Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease |
EP0241201A3 (en) * | 1986-04-07 | 1990-05-23 | Merck & Co. Inc. | Angiotensin converting enzyme inhibitors useful in prolonging survival of mammalians with congestive heart failure |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US4749688A (en) | 1986-06-20 | 1988-06-07 | Schering Corporation | Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension |
CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
DE3633496A1 (en) * | 1986-10-02 | 1988-04-14 | Hoechst Ag | COMBINATION OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS WITH CALCIUMANTAGONISTS AND THEIR USE IN MEDICINAL PRODUCTS |
FR2607004B1 (en) * | 1986-11-20 | 1990-06-01 | Synthelabo | PHARMACEUTICAL COMPOSITIONS CONTAINING DILTIAZEM AND AN ANGIOTENSIN CONVERSION ENZYME INHIBITOR |
DE3704661A1 (en) | 1987-02-14 | 1988-08-25 | Hoechst Ag | FELECTED AZEPINONE AND AZOCINONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR CONTAINERS AND THEIR USE, AND INTERMEDIATE PRODUCTS IN THEIR PRODUCTION |
US4743450A (en) | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
DE3739690A1 (en) | 1987-11-24 | 1989-06-08 | Hoechst Ag | STABILIZED MEDICINAL PRODUCTS, METHOD FOR THEIR PRODUCTION AND STABLE MEDICAL PREPARATIONS |
US5015651A (en) | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
CA1338238C (en) | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
EP0331014A3 (en) * | 1988-03-02 | 1991-10-23 | THERA - Patent Verwaltungs-GmbH | Use of ace inhibitors in diabetes prophylaxis |
US5217958A (en) * | 1988-03-03 | 1993-06-08 | E. R. Squibb & Sons, Inc. | 1,2-hydroxy phosphonates and derivatives thereof |
US4804770A (en) * | 1988-04-29 | 1989-02-14 | E. R. Squibb & Sons, Inc. | Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors |
DE3818245A1 (en) * | 1988-05-28 | 1989-12-07 | Hoechst Ag | COMBINATION OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS WITH COLD CHANNEL MODULATORS AND THEIR USE IN MEDICINAL PRODUCTS |
WO1990005531A1 (en) * | 1988-11-21 | 1990-05-31 | Abbott Laboratories | Method for treating vascular diseases |
IE64514B1 (en) | 1989-05-23 | 1995-08-09 | Zeneca Ltd | Azaindenes |
IL94390A (en) | 1989-05-30 | 1996-03-31 | Merck & Co Inc | Di-substituted imidazo fused 6-membered nitrogen-containing heterocycles and pharmaceutical compositions containing them |
US5064825A (en) | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
CA2016467A1 (en) * | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
EP0403158A3 (en) | 1989-06-14 | 1991-12-18 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
CA2018438C (en) | 1989-06-14 | 2000-08-08 | Joseph Alan Finkelstein | Imidazolyl-alkenoic acids |
KR950009860B1 (en) | 1989-06-30 | 1995-08-29 | 이. 아이. 듀퐁 드 네모아 앤드 캄파니 | Fused-ring aryl substituted imidazoles and process for preparing the same and pharmaceutical compositions comprising same as active ingredient |
ATE134368T1 (en) | 1989-06-30 | 1996-03-15 | Du Pont | SUBSTITUTED IMIDAZOLES AND THEIR USE AS AN ANGIOTENSIN II INHIBITOR |
CA2020073A1 (en) | 1989-07-03 | 1991-01-04 | Eric E. Allen | Substituted quinazolinones as angiotensin ii antagonists |
US5164407A (en) | 1989-07-03 | 1992-11-17 | Merck & Co., Inc. | Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists |
EP0407342A3 (en) | 1989-07-06 | 1991-07-10 | Ciba-Geigy Ag | Pyrimidine derivatives |
EP0409332A3 (en) | 1989-07-19 | 1991-08-07 | Merck & Co. Inc. | Substituted triazoles as angiotensin ii antagonists |
FI94339C (en) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts |
EP0412594B1 (en) | 1989-07-28 | 1996-01-03 | Merck & Co. Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists |
EP0411507B1 (en) | 1989-08-02 | 1994-10-26 | Takeda Chemical Industries, Ltd. | Pyrazole derivatives, their production and use |
NZ234854A (en) | 1989-08-11 | 1993-02-25 | Ici Plc | Quinoline derivatives, preparation, intermediates and pharmaceutical compositions thereof |
DE3926606A1 (en) * | 1989-08-11 | 1991-02-14 | Hoechst Ag | METHOD FOR THE TREATMENT OF CARDIALS AND VASCULAR HYPERTROPHY AND HYPERPLASIA |
US5100897A (en) | 1989-08-28 | 1992-03-31 | Merck & Co., Inc. | Substituted pyrimidinones as angiotensin ii antagonists |
EP0415886A3 (en) | 1989-08-30 | 1991-10-23 | Ciba-Geigy Ag | Aza compounds |
IE70593B1 (en) | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
EP0424317A3 (en) | 1989-10-19 | 1991-09-25 | Ciba-Geigy Ag | Pyrimidines |
US5061694A (en) * | 1989-10-23 | 1991-10-29 | E. R. Squibb & Sons, Inc. | Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor |
US5212165A (en) * | 1989-10-23 | 1993-05-18 | E. R. Squibb & Sons, Inc. | Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor |
IL95975A (en) | 1989-10-24 | 1997-06-10 | Takeda Chemical Industries Ltd | N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them |
AU640417B2 (en) | 1989-10-25 | 1993-08-26 | Smithkline Beecham Corporation | Substituted 5-((tetrazolyl)alkenyl)imidazoles |
CA2026686A1 (en) * | 1989-10-30 | 1991-05-01 | Werner Tschollar | Method for preventing onset of type ii diabetes employing an ace inhibitor |
IL96019A0 (en) | 1989-10-31 | 1991-07-18 | Fujisawa Pharmaceutical Co | Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
CA2028925A1 (en) | 1989-11-06 | 1991-05-07 | Gerald R. Girard | Substituted n-(imidazolyl)alkyl alanine derivatives |
PT95899A (en) | 1989-11-17 | 1991-09-13 | Glaxo Group Ltd | PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES |
IE903911A1 (en) | 1989-11-20 | 1991-05-22 | Ici Plc | Diazine derivatives |
US5073566A (en) | 1989-11-30 | 1991-12-17 | Eli Lilly And Company | Angiotensin ii antagonist 1,3-imidazoles and use thereas |
EP0430709A3 (en) | 1989-12-01 | 1992-02-12 | Glaxo Group Limited | Benzthiophen derivatives |
GB8927277D0 (en) | 1989-12-01 | 1990-01-31 | Glaxo Group Ltd | Chemical compounds |
EP0430300A3 (en) | 1989-12-01 | 1992-03-25 | Takeda Chemical Industries, Ltd. | Xanthine derivatives, their production and use |
US5104891A (en) | 1989-12-11 | 1992-04-14 | G. D. Searle & Co. | Cycloheptimidazolone compounds as angiotensin ii antagonists for control of hypertension |
EP0434038A1 (en) | 1989-12-22 | 1991-06-26 | Takeda Chemical Industries, Ltd. | Fused imidazole derivatives, their production and use |
EP0435827A3 (en) | 1989-12-28 | 1991-11-13 | Ciba-Geigy Ag | Diaza compounds |
CA2032289A1 (en) | 1989-12-29 | 1991-06-30 | Joseph A. Finkelstein | Substituted 5-(alkyl) carboxamide imidazoles |
JPH05504359A (en) | 1990-02-13 | 1993-07-08 | メルク・エンド・カムパニー・インコーポレーテツド | Imidazole angiotensin 2 antagonists containing substituted benzyl moieties |
JP2726563B2 (en) | 1990-02-13 | 1998-03-11 | メルク・エンド・カムパニー・インコーポレーテツド | Triazole angiotensin containing substituted benzyl element (II) antagonist |
JPH05503530A (en) | 1990-02-13 | 1993-06-10 | メルク・エンド・カムパニー・インコーポレーテツド | Angiotensin 2 antagonist containing substituted benzyl component |
ES2081365T3 (en) | 1990-02-14 | 1996-03-01 | Siemens Ag | PROCEDURE FOR THE DEMODULATION OF CODED-SECAM COLORED TELEVISION SIGNS WITH LINKED CYCLE OF LINES AND CIRCUIT PROVISION FOR THE PERFORMANCE OF THE PROCEDURE. |
CA2036304C (en) | 1990-02-15 | 2001-04-17 | Takehiko Naka | Pyrimidinedione derivatives, their production and use |
DE122007000050I1 (en) | 1990-02-19 | 2007-11-08 | Novartis Ag | acyl compounds |
CA2036618C (en) | 1990-02-22 | 2002-10-29 | Akira Morimoto | Fused thiophene derivatives, their production and use |
DE4006693A1 (en) | 1990-03-01 | 1991-09-05 | Schering Ag | NEW BENZIMIDAZOLE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE |
US5044166A (en) | 1990-03-05 | 1991-09-03 | Membrane Technology & Research, Inc. | Refrigeration process with purge and recovery of refrigerant |
CA2037630C (en) | 1990-03-07 | 2001-07-03 | Akira Morimoto | Nitrogen-containing heterocylic compounds, their production and use |
GB9005354D0 (en) | 1990-03-09 | 1990-05-02 | Glaxo Group Ltd | Chemical compounds |
FR2659655B1 (en) | 1990-03-19 | 1992-07-24 | Union Pharma Scient Appl | NOVEL ANGIOTENSIN II RECEPTOR ANTAGONIST OXYPYRAZOLE DERIVATIVES; THEIR PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
PT97078B (en) | 1990-03-20 | 1997-07-31 | Sanofi Sa | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US5223516A (en) | 1990-03-22 | 1993-06-29 | E. R. Squibb & Sons, Inc. | 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same |
EP0522038A4 (en) | 1990-03-30 | 1993-05-26 | Merck & Co. Inc. | Substituted pyrimidines, pyrimidinones and pyridopyrimidines |
JPH05505822A (en) | 1990-03-30 | 1993-08-26 | メルク・エンド・カムパニー・インコーポレーテツド | Pyrazoles, isoxazoles and isothiazole substituted products |
DE4010797A1 (en) | 1990-04-04 | 1991-10-10 | Hoechst Ag | SUBSTITUTED AZOLES, METHOD FOR THE PRODUCTION THEREOF, MEANS CONTAINING THEM AND THE USE THEREOF |
CA2077897A1 (en) | 1990-04-13 | 1991-10-14 | Robert G. Franz | Substituted benzimidazoles |
US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
EP0453210A3 (en) | 1990-04-19 | 1993-01-13 | Imperial Chemical Industries Plc | Pyridine derivatives |
US5703110A (en) | 1990-04-27 | 1997-12-30 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
US5098920A (en) | 1990-05-04 | 1992-03-24 | G. D. Searle & Co. | 1h-substituted-1,2,4-triazole compounds and methods of use thereof for treatment of cardiovascular disorders |
GB9010394D0 (en) | 1990-05-09 | 1990-06-27 | Ici Plc | Heterocyclic compounds |
CA2041763A1 (en) | 1990-05-11 | 1991-11-12 | Sheih-Shung T. Chen | Microbial transformation process for antihypertensive products |
US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
JPH05506443A (en) | 1990-05-25 | 1993-09-22 | ジー.ディー.サール アンド カンパニー | N-substituted 1,2,4-triazolone compounds for the treatment of cardiovascular disorders |
US5140012A (en) * | 1990-05-31 | 1992-08-18 | E. R. Squibb & Sons, Inc. | Method for preventing onset of restenosis after angioplasty employing pravastatin |
US5166143A (en) * | 1990-05-31 | 1992-11-24 | E. R. Squibb & Sons, Inc. | Method for preventing onset of restenosis after angioplasty employing an ace inhibitor |
JPH04235974A (en) | 1990-06-08 | 1992-08-25 | Roussel Uclaf | New benzimidazole derivatives, process for producing same, obtained new intermediates, use thereof as medicines and pharmaceutical compositions containing same |
ES2121773T3 (en) | 1990-06-08 | 1998-12-16 | Hoechst Marion Roussel Inc | DERIVATIVES OF BENCIMIDAZOLE, ITS PREPARATION PROCEDURE, INTERMEDIATE PRODUCTS, ITS APPLICATION AS DRUGS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
WO1991019715A1 (en) | 1990-06-15 | 1991-12-26 | G.D. Searle & Co. | 1H-SUBSTITUTED-IMIDAZO[4,5-d]PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS |
CN1034934C (en) | 1990-06-19 | 1997-05-21 | 明治制果株式会社 | Pyridine derivatives having angiotensin II antagonism |
CA2085584C (en) | 1990-06-22 | 2003-02-11 | David John Carini | Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists |
NZ238688A (en) | 1990-06-28 | 1992-05-26 | Smithkline Beecham Corp | Substituted histidines: pharmaceutical compositions, preparation and uses thereof |
IE912114A1 (en) | 1990-07-02 | 1992-01-15 | Union Pharma Scient Appl | Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present |
IL98319A (en) | 1990-07-05 | 1997-04-15 | Roussel Uclaf | Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them |
US5137902A (en) | 1990-07-13 | 1992-08-11 | E. I. Du Pont De Nemours And Company | 4-alkylimidazole derivatives and anti-hypertensive use thereof |
CA2044806A1 (en) | 1990-07-18 | 1992-01-19 | Roland Jaunin | Purine derivatives |
CA2047029A1 (en) | 1990-07-19 | 1992-01-20 | Shieh-Shung T. Chen | Microbial transformation process for antihypertensive products |
DE4023215A1 (en) | 1990-07-21 | 1992-01-23 | Hoechst Ag | New substd. azole derivs. angiotensin II antagonists - for treating hypertension, coronary insufficiency, myocardial infarct, coronary hypertrophy, arteriosclerosis etc. |
RU1836357C (en) | 1990-07-23 | 1993-08-23 | Др.Карл Томэ ГмбХ | Benzimidazole derivatives, their isomers, mixtures of isomers, hydrates or their physiologically bearable salts possessing properties antagonistic to angiotenzine |
NZ239161A (en) | 1990-07-31 | 1994-01-26 | Smithkline Beecham Corp | Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments, |
EP0470543A1 (en) | 1990-08-10 | 1992-02-12 | Dr. Karl Thomae GmbH | Heterocyclic imidazoles, remedies containing them and processes for their preparation |
US5217985A (en) | 1990-08-28 | 1993-06-08 | G. D. Searle & Co. | Renal-selective biphenylalkyl 1h-substituted-1,2,4-triazole angiotensin ii antagonists for treatment of hypertension |
WO1992004343A1 (en) | 1990-09-04 | 1992-03-19 | Yamanouchi Pharmaceutical Co., Ltd. | Novel tetrahydrobenzazole derivative |
CA2048699A1 (en) * | 1990-09-04 | 1992-03-05 | Abraham Sudilovsky | Method for preventing or treating cerebro-vascular disease employing ceronapril |
IE912956A1 (en) | 1990-09-10 | 1992-03-11 | Abbott Lab | Angiotensin ii receptor antagonists |
IL99372A0 (en) | 1990-09-10 | 1992-08-18 | Ciba Geigy Ag | Azacyclic compounds |
US5140036A (en) | 1990-09-19 | 1992-08-18 | G. D. Searle & Co. | 1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
US5210092A (en) | 1990-09-25 | 1993-05-11 | Fujisawa Pharmaceutical Co., Ltd. | Angiotensin ii antagonizing heterocyclic derivatives |
US5242939A (en) | 1990-09-28 | 1993-09-07 | Warner-Lambert Company | Anilide derivatives with angiotensin ii antagonist properties |
US5126342A (en) | 1990-10-01 | 1992-06-30 | Merck & Co., Inc. | Imidazole angiotensin ii antagonists incorporating acidic functional groups |
EP0481614A1 (en) | 1990-10-01 | 1992-04-22 | Merck & Co. Inc. | Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists |
US5260322A (en) | 1990-10-08 | 1993-11-09 | Merck & Co., Inc. | Angiotension II antagonists in the treatment of hyperuricemia |
CA2053148A1 (en) | 1990-10-16 | 1992-04-17 | Karnail Atwal | Dihydropyrimidine derivatives |
US5470975A (en) * | 1990-10-16 | 1995-11-28 | E.R. Squibb & Sons, Inc. | Dihydropyrimidine derivatives |
CA2053340C (en) | 1990-10-18 | 2002-04-02 | Timothy P. Burkholder | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
US5430145A (en) | 1990-10-18 | 1995-07-04 | Merrell Dow Pharmaceuticals Inc. | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
CA2052014A1 (en) * | 1990-10-19 | 1992-04-20 | Henry Y. Pan | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
US5190970A (en) * | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
US5130333A (en) * | 1990-10-19 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Method for treating type II diabetes employing a cholesterol lowering drug |
AU9024591A (en) | 1990-10-25 | 1992-05-26 | G.D. Searle & Co. | Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders |
AU636066B2 (en) | 1990-10-30 | 1993-04-08 | Takeda Chemical Industries Ltd. | Thienoimidazole derivatives, their production and use |
US5087634A (en) | 1990-10-31 | 1992-02-11 | G. D. Searle & Co. | N-substituted imidazol-2-one compounds for treatment of circulatory disorders |
PH31175A (en) | 1990-10-31 | 1998-03-20 | Squibb & Sons Inc | Indole and benzimi-dazole-substituted imidazole and benzimidazole derivatives. |
DE4036645A1 (en) | 1990-11-16 | 1992-05-21 | Hoechst Ag | SUBSTITUTED AZOLE, METHOD FOR THE PRODUCTION THEREOF, THE AGENT, AND THEIR USE THEREOF |
DE4036706A1 (en) | 1990-11-17 | 1992-05-21 | Hoechst Ag | METHOD FOR THE TREATMENT OF CARDIALS AND VASCULAR HYPERTROPHY AND HYPERPLASIA |
GB9025123D0 (en) | 1990-11-19 | 1991-01-02 | Ici Plc | Nitrogen compounds |
GB9026006D0 (en) | 1990-11-29 | 1991-01-16 | Glaxo Group Ltd | Chemical compounds |
WO1992009278A1 (en) | 1990-11-30 | 1992-06-11 | Smithkline Beecham Corporation | Substituted 5-aryl imidazoles |
CA2057089A1 (en) | 1990-12-07 | 1992-06-08 | Eric E. Allen | Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists |
DE69133019T2 (en) | 1990-12-14 | 2002-11-28 | Smithkline Beecham Corp., Philadelphia | IMIDAZOLYL-alkene carboxylic acids |
AU657498B2 (en) | 1990-12-14 | 1995-03-16 | Novartis Ag | Biphenylyl compounds |
US5175180A (en) | 1990-12-20 | 1992-12-29 | G. D. Searle & Co. | N-substituted n-(alpha-triazolyl-toluyl)pyrrole compounds and use for treatment of circulatory disorders |
CA2058198A1 (en) | 1991-01-04 | 1992-07-05 | Adalbert Wagner | Azole derivatives, process for their preparation, and their use |
US5124335A (en) | 1991-01-30 | 1992-06-23 | Merck & Co., Inc. | Substituted pyrollo-fused 6 membered heterocycles as angiotensin ii antagonists |
US5290780A (en) | 1991-01-30 | 1994-03-01 | American Cyanamid Co. | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
AT395853B (en) | 1991-01-31 | 1993-03-25 | Chem Pharm Forsch Gmbh | NEW IMIDAZOLE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE |
SI9210098B (en) | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoles, drugs with this compounds, and process for their preparation |
IL100555A (en) | 1991-02-07 | 2000-08-31 | Hoechst Marion Roussel Inc | N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them |
ATE156120T1 (en) | 1991-02-07 | 1997-08-15 | Roussel Uclaf | BIZYCLIC NITROGEN COMPOUNDS, THEIR PRODUCTION, INTERMEDIATE PRODUCTS OBTAINED, THEIR USE AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
MX9200299A (en) | 1991-02-07 | 1992-12-01 | Roussel Uclaf | NEW NITROGENATED BICYCLE DERIVATIVES, THEIR PROCEDURE FOR PREPARING THE NEW INTERMEDIATE COMPOUNDS OBTAINED THEIR APPLICATION AS MEDICINES AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. |
IE920175A1 (en) | 1991-02-11 | 1992-08-12 | Zeneca Ltd | Nitrogen heterocycles |
GB9102803D0 (en) | 1991-02-11 | 1991-03-27 | Ici Plc | Pyridine compounds |
GB9102804D0 (en) | 1991-02-11 | 1991-03-27 | Ici Plc | Heterocyclic derivatives |
IL100917A0 (en) | 1991-02-16 | 1992-11-15 | Fisons Plc | Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them |
FR2672892B1 (en) | 1991-02-20 | 1994-01-14 | Synthelabo | DERIVATIVES OF 4-PYRIMIDINONES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION. |
IE920540A1 (en) | 1991-02-21 | 1992-08-26 | Sankyo Co | 1-biphenylmethylimidazole derivatives, their preparation and¹their therapetuic use |
CA2061159A1 (en) | 1991-02-26 | 1992-08-27 | Michael A. Poss | Imidazole and benzimidazole derivatives |
FR2673427B1 (en) | 1991-03-01 | 1993-06-18 | Sanofi Elf | N-SUBSTITUTED DIAZOTATED HETEROCYCLIC DERIVATIVES BY A BIPHENYLMETHYL GROUP, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. |
US5202328A (en) | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
EP0502575A1 (en) | 1991-03-06 | 1992-09-09 | Merck & Co. Inc. | Substituted 1-(2H)-isoquinolinones |
EP0503838A3 (en) | 1991-03-08 | 1992-10-07 | Merck & Co. Inc. | Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists |
EP0505098A1 (en) | 1991-03-19 | 1992-09-23 | Merck & Co. Inc. | Imidazole derivatives bearing acidic functional groups as angiotensin II antagonists |
US5196537A (en) | 1991-03-21 | 1993-03-23 | G. D. Searle & Co. | 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
US5187179A (en) | 1991-03-22 | 1993-02-16 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted imidazo [1,2-b][1,2,4]triazole |
US5128327A (en) | 1991-03-25 | 1992-07-07 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle |
AU1417092A (en) | 1991-03-25 | 1992-10-21 | Glaxo Group Limited | 1-imidazolgemethyl benzofuran derivatives as inhibitors of angiotensin ii activity |
US5177074A (en) | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
DE4110019C2 (en) | 1991-03-27 | 2000-04-13 | Merck Patent Gmbh | Imidazopyridines, processes for their production and pharmaceutical preparations containing them |
US5157025A (en) * | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
US5157040A (en) | 1991-04-05 | 1992-10-20 | Merck & Co., Inc. | Substituted quinolines as angiotensin ii antagonists |
US5164403A (en) | 1991-04-05 | 1992-11-17 | G. D. Searle & Co. | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders |
US5151435A (en) | 1991-04-08 | 1992-09-29 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating an indole or dihydroindole |
US5155117A (en) | 1991-04-12 | 1992-10-13 | G. D. Searle & Co. | 1-arylheteroarylalkyl substituted-1h-1,2,4-triazole compounds for treatment of circulatory disorders |
TW274551B (en) | 1991-04-16 | 1996-04-21 | Takeda Pharm Industry Co Ltd | |
DE4200954A1 (en) | 1991-04-26 | 1992-10-29 | Bayer Ag | New heterocycle-substd. phenylacetic acid derivs. - are angiotensin II antagonists for treating arterial hypertonia, atherosclerosis, coronary insufficiency, ischaemic cerebral disorders, respiratory disorders, etc. |
US5252574A (en) | 1991-04-26 | 1993-10-12 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted thiophene or furan |
CZ227093A3 (en) | 1991-04-29 | 1994-03-16 | Merck & Co Inc | Mixture suitable for the preparation of tablets by direct moulding |
GB9109246D0 (en) | 1991-04-30 | 1991-06-19 | Ici Plc | Nitrogen derivatives |
US5198438A (en) | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
US5162325A (en) | 1991-05-07 | 1992-11-10 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted benzyl element |
JPH05112533A (en) | 1991-05-08 | 1993-05-07 | Upjohn Co:The | Imidazobenzoquinoline and agent for preventing and treating hypertension and conjestive heart failure containing same as effective component |
US5506361A (en) * | 1991-05-08 | 1996-04-09 | Theupjohn Company | Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same |
US5223501A (en) | 1991-05-10 | 1993-06-29 | Merck & Co., Inc. | Substituted pyrimidinones bearing acidic functional groups as angiotensin ii antagonists |
US5238942A (en) | 1991-05-10 | 1993-08-24 | Merck & Co., Inc. | Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists |
US5162340A (en) | 1991-05-10 | 1992-11-10 | Merck & Co., Inc. | Substituted 1-(2h)-isoquinolinones bearing acidic functional groups as angiotensin ii antagonists |
GB9110532D0 (en) | 1991-05-15 | 1991-07-03 | Smithkline Beecham Corp | Chemical compounds |
GB9110623D0 (en) | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
EP0514192A1 (en) | 1991-05-16 | 1992-11-19 | Glaxo Group Limited | Antihypertensive benzofuran derivatives, substituted by varied N-pyrimidinyl- or N-imidazolyl-methyl groups |
GB9110625D0 (en) | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
GB9110635D0 (en) | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
MX9202300A (en) | 1991-05-16 | 1992-11-01 | Glaxo Group Ltd | DERIVATIVES OF BENZOFURANO, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM. |
GB9110636D0 (en) | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
FR2676734B1 (en) | 1991-05-23 | 1995-05-19 | Roussel Uclaf | NEW PYRIMIDINE DERIVATIVES, THEIR PREPARATION PROCESS, THE NEW INTERMEDIATES OBTAINED, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
AU1625192A (en) | 1991-05-31 | 1992-12-03 | Zeneca Limited | Heterocyclic derivatives |
WO1992021666A1 (en) | 1991-05-31 | 1992-12-10 | Laboratoires Upsa | Angiotensin ii receptor antagonist thiazole devivatives |
US5175164A (en) | 1991-06-05 | 1992-12-29 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted indole or dihydroindole |
JPH05213884A (en) | 1991-06-14 | 1993-08-24 | Upjohn Co:The | Novel 4-aminoquinoline and prophylatic/ therapeutic agent for hypertensive/congestive heart failure using same as effective component |
US5210211A (en) | 1991-06-21 | 1993-05-11 | Warner-Lambert Company | 4-(1h-pyrrol-1-yl) imidazoles with angiotension ii antagonist activity |
GB9113626D0 (en) | 1991-06-25 | 1991-08-14 | Ici Plc | Heterocyclic compounds |
GB9113628D0 (en) | 1991-06-25 | 1991-08-14 | Ici Plc | Heterocyclic derivatives |
IL102183A (en) | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them |
WO1993001177A1 (en) | 1991-07-03 | 1993-01-21 | Merck & Co., Inc. | Substituted triazolinones |
FR2678618B1 (en) | 1991-07-05 | 1993-11-05 | Upsa Laboratoires | NOVEL TRIAZOLO PYRIMIDINE DERIVATIVES ANTIAGONISTS OF ANGIOTENSIN II RECEPTORS; THEIR PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
WO1993003033A1 (en) | 1991-07-26 | 1993-02-18 | G. D. Searle & Co. | CARBONATE-SUBSTITUTED IMIDAZO[4,5-d] PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS |
IT1250749B (en) | 1991-08-02 | 1995-04-21 | Luso Farmaco Inst | HETEROCYCLIC COMPOUNDS ACTIVATED IN II ANTAGONIST |
WO1993003040A1 (en) | 1991-08-05 | 1993-02-18 | Taisho Pharmaceutical Co., Ltd. | Thienopyrimidin-4-one derivative |
US5225401A (en) | 1991-08-12 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Treatment of congestive heart failure |
US5246944A (en) | 1991-08-13 | 1993-09-21 | Merck & Co., Inc. | Quinoline angiotensin ii antagonists incorporating a substituted benzyl element |
DE59208448D1 (en) | 1991-08-15 | 1997-06-12 | Ciba Geigy Ag | N-acyl-N-heterocyclyl or naphthylalkyl amino acids as angiotensin II antagonists |
DE69223575T2 (en) | 1991-09-20 | 1998-04-16 | Lgl Electronics Spa | Self-regulating thread brake for a weft feed device |
US5202322A (en) * | 1991-09-25 | 1993-04-13 | Merck & Co., Inc. | Quinazolinone and pyridopyrimidine a-II antagonists |
US5256667A (en) * | 1991-09-25 | 1993-10-26 | Merck & Co., Inc. | Quinazolinones and pyridopyrimidinones |
AU657793B2 (en) | 1991-09-27 | 1995-03-23 | Merrell Pharmaceuticals Inc. | Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE |
ZA927211B (en) | 1991-09-27 | 1993-03-24 | Merrell Dow Pharma | Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE. |
JPH06107661A (en) * | 1991-10-24 | 1994-04-19 | Upjohn Co:The | Imidazole derivative and medicinal composition having same as effective component |
US5219856A (en) * | 1992-04-06 | 1993-06-15 | E. I. Du Pont De Nemours And Company | Angiotensin-II receptor blocking, heterocycle substituted imidazoles |
US5972990A (en) * | 1992-04-10 | 1999-10-26 | Brigham And Women's Hospital, Inc. | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
US5977160A (en) * | 1992-04-10 | 1999-11-02 | Brigham And Women's Hospital, Inc. | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
US5552397A (en) | 1992-05-18 | 1996-09-03 | E. R. Squibb & Sons, Inc. | Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase |
EP0640086B1 (en) | 1992-05-15 | 1999-08-04 | Merrell Pharmaceuticals Inc. | MERCAPTOACETYLAMIDO PYRIDAZO[ 1,2-a][1,2]DIAZEPINE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE |
EP0668864A1 (en) * | 1992-07-17 | 1995-08-30 | Merck & Co. Inc. | Substituted biphenylmethylimidazopyridines |
US5266583A (en) * | 1992-09-01 | 1993-11-30 | Merck & Co., Inc. | Angitotensin II antagonist |
US5504080A (en) | 1992-10-28 | 1996-04-02 | Bristol-Myers Squibb Co. | Benzo-fused lactams |
DE4308504A1 (en) * | 1993-03-18 | 1994-09-22 | Knoll Ag | New use of a combination of verapamil and trandolapril |
DE4309553A1 (en) * | 1993-03-24 | 1994-09-29 | Bayer Ag | Process for the preparation of 3R, 5S - (+) - sodium erythro- (E) -7- (4- (4-flurophenyl) -2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl) -3, 5-dihydroxy-hept-6-enoate |
KR0156780B1 (en) | 1993-06-11 | 1998-11-16 | 나이토 하루오 | Amino acid derivatives |
US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
US5362727A (en) | 1993-07-26 | 1994-11-08 | Bristol-Myers Squibb | Substituted azepino[2,1-a]isoquinoline compounds |
US5525723A (en) | 1993-11-18 | 1996-06-11 | Bristol-Myers Squibb Co. | Compounds containing a fused multiple ring lactam |
US6369103B1 (en) * | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
ES2079315B1 (en) * | 1994-02-24 | 1996-10-16 | Uriach & Cia Sa J | NEW IMIDAZOPIRIDINES. |
ES2105939B1 (en) * | 1994-08-02 | 1998-07-01 | Uriach & Cia Sa J | NEW PIRAZOLES WITH ANTAGONIST ACTIVITY OF ANGIOTENSIN II. |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
DK0808172T3 (en) * | 1995-02-10 | 2003-10-20 | Searle & Co | Combinations of Angiotensin Converting Enzyme Inhibitor and Side Effect Reducing Amount of Aldesterone Antagonist |
EP0738510A3 (en) * | 1995-04-20 | 2005-12-21 | L'oreal | Use of a HMG-CoA reductase inhibitor as an anti-ageing agent and as an anti-acne agent. Composition comprising at least one HMG-CoA reductase inhibitor and at least one active substance with scaling properties. |
US5656603A (en) * | 1995-05-31 | 1997-08-12 | Loyola University Of Chicago | Aminopeptidase P inhibitors and uses thereof |
TW442301B (en) * | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
GB2308064A (en) * | 1995-10-31 | 1997-06-18 | Merck & Co Inc | Treatment of congestive heart failure with a growth hormone secretagogue |
AU2252297A (en) * | 1996-01-31 | 1997-08-22 | Technology Licensing Co., L.L.C. | Method of diagnosis and treatment and related compositions and apparatus |
EP0795327A1 (en) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
CA2257946A1 (en) * | 1996-06-24 | 1997-12-31 | Merck & Co., Inc. | A composition of enalapril and losartan |
ES2200310T3 (en) * | 1997-01-10 | 2004-03-01 | MERCK & CO., INC. | USE OF ANTAGONISTS OF ANGIOTENSIN II LOSARTAN AND EXP-3174 IN THE TREATMENT OF SYMPTOMATIC CARDIAC INSUFFICIENCY. |
US6180660B1 (en) * | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
JP5187991B2 (en) * | 1997-10-17 | 2013-04-24 | アーク・セラピューティックス・リミテッド | Use of renin-angiotensin system inhibitors |
US6097772A (en) * | 1997-11-24 | 2000-08-01 | Ericsson Inc. | System and method for detecting speech transmissions in the presence of control signaling |
JPH11222439A (en) * | 1998-02-03 | 1999-08-17 | Dainippon Pharmaceut Co Ltd | Inhibitor of cerebral vasospasm |
AU2745199A (en) * | 1998-03-04 | 1999-09-20 | Takeda Chemical Industries Ltd. | Sustained-release preparation for aii antagonist, production and use thereof |
PT1096932E (en) * | 1998-07-10 | 2007-09-21 | Novartis Pharma Ag | Antihypertensive combination of valsartan and calcium channel blocker |
DE19913528A1 (en) * | 1998-12-21 | 2000-06-29 | Sanol Arznei Schwarz Gmbh | Treatment of cerebrovascular disease, e.g. due to cerebral ischemia, uses low dosage of the angiotensin converting enzyme inhibitor moexipril |
WO2000071751A1 (en) * | 1999-05-21 | 2000-11-30 | Myriad Genetics, Inc. | Diabetes gene |
KR20020040795A (en) * | 1999-08-30 | 2002-05-30 | 로버트 흐라이탁, 미쉘 베스트 | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
GB0020691D0 (en) * | 2000-08-22 | 2000-10-11 | Boehringer Ingelheim Pharma | Pharmaceutical combination |
US20030158090A1 (en) * | 2001-07-23 | 2003-08-21 | Ulrik Pedersen-Bjergaard | Renin-angiotensin system in diabetes mellitus |
US20050065203A1 (en) * | 2001-10-17 | 2005-03-24 | Salim Yusuf | Method of reducing type 2 diabetes in high risk patients |
AU2002364381A1 (en) * | 2001-11-23 | 2003-06-10 | Solvay Pharmaceuticals Gmbh | Hypertonia treatment during the acute phase of a cerebrovascular accident |
ITBO20030050A1 (en) * | 2003-02-06 | 2004-08-07 | Ima Spa | MACHINE FOR THE TREATMENT OF PHARMACEUTICAL PRODUCTS. |
-
1999
- 1999-08-27 SE SE9903028A patent/SE9903028D0/en unknown
-
2000
- 2000-08-25 AT AT04006330T patent/ATE554761T1/en active
- 2000-08-25 EE EEP200200085A patent/EE05130B1/en not_active IP Right Cessation
- 2000-08-25 DK DK04006330.7T patent/DK1437131T3/en active
- 2000-08-25 TR TR2002/02464T patent/TR200202464T2/en unknown
- 2000-08-25 ES ES08004265.8T patent/ES2525699T3/en not_active Expired - Lifetime
- 2000-08-25 ES ES00965898.0T patent/ES2250192T5/en not_active Expired - Lifetime
- 2000-08-25 TR TR2002/02466T patent/TR200202466T2/en unknown
- 2000-08-25 CN CNA2008101259535A patent/CN101537181A/en active Pending
- 2000-08-25 AU AU76484/00A patent/AU7648400A/en not_active Abandoned
- 2000-08-25 SK SK270-2002A patent/SK288239B6/en not_active IP Right Cessation
- 2000-08-25 EP EP10010670A patent/EP2277519A3/en not_active Withdrawn
- 2000-08-25 KR KR1020027002521A patent/KR20020060167A/en active Search and Examination
- 2000-08-25 TR TR2002/02467T patent/TR200202467T2/en unknown
- 2000-08-25 RU RU2002107673/15A patent/RU2272651C2/en not_active IP Right Cessation
- 2000-08-25 PT PT80042658T patent/PT1925303E/en unknown
- 2000-08-25 DK DK00965898.0T patent/DK1212081T4/en active
- 2000-08-25 CA CA002382387A patent/CA2382387C/en not_active Expired - Fee Related
- 2000-08-25 CZ CZ20020644A patent/CZ303433B6/en not_active IP Right Cessation
- 2000-08-25 KR KR1020087007837A patent/KR20080035703A/en not_active Application Discontinuation
- 2000-08-25 DK DK08004265.8T patent/DK1925303T3/en active
- 2000-08-25 EP EP04006330A patent/EP1437131B1/en not_active Expired - Lifetime
- 2000-08-25 TR TR2002/02463T patent/TR200202463T2/en unknown
- 2000-08-25 ES ES04006330T patent/ES2386141T3/en not_active Expired - Lifetime
- 2000-08-25 ME MEP-2008-282A patent/ME00181B/en unknown
- 2000-08-25 EP EP08004265.8A patent/EP1925303B1/en not_active Expired - Lifetime
- 2000-08-25 AT AT00965898T patent/ATE307604T1/en active
- 2000-08-25 TR TR2002/00518T patent/TR200200518T2/en unknown
- 2000-08-25 DE DE60023518.1T patent/DE60023518T3/en not_active Expired - Lifetime
- 2000-08-25 RS RS3602A patent/RS52907B/en unknown
- 2000-08-25 IL IL148126A patent/IL148126A/en not_active IP Right Cessation
- 2000-08-25 NZ NZ571901A patent/NZ571901A/en not_active IP Right Cessation
- 2000-08-25 WO PCT/EP2000/008341 patent/WO2001015673A2/en active IP Right Grant
- 2000-08-25 SI SI200031069T patent/SI1437131T1/en unknown
- 2000-08-25 SI SI200031084T patent/SI1925303T1/en unknown
- 2000-08-25 JP JP2001519887A patent/JP4843172B2/en not_active Expired - Fee Related
- 2000-08-25 CN CNB008110700A patent/CN100408093C/en not_active Expired - Fee Related
- 2000-08-25 PL PL00353066A patent/PL353066A1/en not_active IP Right Cessation
- 2000-08-25 PT PT04006330T patent/PT1437131E/en unknown
- 2000-08-25 EP EP00965898.0A patent/EP1212081B2/en not_active Expired - Lifetime
- 2000-08-25 BR BR0013540-2A patent/BR0013540A/en not_active Application Discontinuation
- 2000-08-25 SI SI200030766T patent/SI1212081T2/en unknown
- 2000-08-25 MX MXPA02001633A patent/MXPA02001633A/en active IP Right Grant
- 2000-08-25 UA UA2002032397A patent/UA76702C2/en unknown
- 2000-08-25 HU HU0202461A patent/HU229107B1/en not_active IP Right Cessation
-
2002
- 2002-01-16 YU YU3602A patent/YU3602A/en unknown
- 2002-01-18 BG BG106319A patent/BG66115B1/en unknown
- 2002-01-18 BG BG11047909A patent/BG110479A/en unknown
- 2002-02-21 ZA ZA200201471A patent/ZA200201471B/en unknown
- 2002-02-21 NO NO20020850A patent/NO329245B1/en not_active IP Right Cessation
- 2002-02-26 HR HR20020169A patent/HRP20020169A2/en not_active Application Discontinuation
-
2003
- 2003-04-10 HK HK03102600.5A patent/HK1050327A1/en not_active IP Right Cessation
-
2005
- 2005-08-17 AU AU2005203694A patent/AU2005203694A1/en not_active Abandoned
- 2005-09-08 RU RU2005128124/15A patent/RU2378018C2/en not_active IP Right Cessation
-
2006
- 2006-02-20 UA UAA200601774A patent/UA88270C2/en unknown
- 2006-05-02 US US11/415,137 patent/US20060194868A1/en not_active Abandoned
-
2008
- 2008-02-07 US US12/027,938 patent/US20080125472A1/en not_active Abandoned
-
2009
- 2009-02-12 AU AU2009200551A patent/AU2009200551B2/en not_active Ceased
- 2009-06-16 US US12/457,589 patent/US20090258919A1/en not_active Abandoned
- 2009-11-10 US US12/615,588 patent/US20100267798A1/en not_active Abandoned
-
2010
- 2010-04-20 NO NO20100569A patent/NO20100569L/en not_active Application Discontinuation
- 2010-12-01 US US12/957,777 patent/US20110263619A1/en not_active Abandoned
-
2012
- 2012-07-24 CY CY20121100657T patent/CY1112987T1/en unknown
- 2012-11-09 US US13/673,852 patent/US20130317047A1/en not_active Abandoned
-
2014
- 2014-12-23 CY CY20141101082T patent/CY1115869T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009200551B2 (en) | Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure | |
AU710846B2 (en) | Novel medical use of an ace-inhibitor for treatment of dyspeptic symptoms | |
CA2500709A1 (en) | Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure | |
WO2005020971A1 (en) | Use of an angiotensin ii antagonist for the prevention of myocardial infarction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20160825 |